Madhurima Chatterjee,Selcuk Özdemir,Christian Fritz,Wiebke Möbius,Luca Kleineidam,Eckhard Mandelkow,Jacek Biernat,Cem Doğdu,Oliver Peters,Nicoleta Carmen Cosma,Xiao Wang,Luisa-Sophia Schneider,Josef Priller,Eike Spruth,Andrea A. Kühn,Patricia Krause,Thomas Klockgether,Ina R. Vogt,Okka Kimmich,Annika Spottke,Daniel C. Hoffmann,Klaus Fliessbach,Carolin Miklitz,Cornelia McCormick,Patrick Weydt,Björn Falkenburger,Moritz Brandt,René Guenther,Elisabeth Dinter,Jens Wiltfang,Niels Hansen,Mathias Bähr,Inga Zerr,Agnes Flöel,Peter J. Nestor,Emrah Düzel,Wenzel Glanz,Enise Incesoy,Katharina Bürger,Daniel Janowitz,Robert Perneczky,Boris S. Rauchmann,Franziska Hopfner,Olivia Wagemann,Johannes Levin,Stefan Teipel,Ingo Kilimann,Doreen Goerss,Johannes Prudlo,Thomas Gasser,Kathrin Brockmann,David Mengel,Milan Zimmermann,Matthis Synofzik,Carlo Wilke,Judit Selma-González,Janina Turon-Sans,Miguel Angel Santos-Santos,Daniel Alcolea,Sara Rubio-Guerra,Juan Fortea,Álvaro Carbayo,Alberto Lleó,Ricardo Rojas-García,Ignacio Illán-Gala,Michael Wagner,Ingo Frommann,Sandra Roeske,Lucas Bertram,Michael T. Heneka,Frederic Brosseron,Alfredo Ramirez,Matthias Schmid,Rudi Beschorner,Annett Halle,Jochen Herms,Manuela Neumann,Nicolas R. Barthélemy,Randall J. Bateman,Patrizia Rizzu,Peter Heutink,Oriol Dols-Icardo,Günter Höglinger,Andreas Hermann,Anja Schneider

Abstract:Minimally invasive biomarkers are urgently needed to detect molecular pathology in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Here, we show that plasma extracellular vesicles (EVs) contain quantifiable amounts of TDP-43 and full-length tau, which allow the quantification of 3-repeat (3R) and 4-repeat (4R) tau isoforms. Plasma EV TDP-43 levels and EV 3R/4R tau ratios were determined in a cohort of 704 patients, including 37 genetically and 31 neuropathologically proven cases. Diagnostic groups comprised patients with TDP-43 proteinopathy ALS, 4R tauopathy progressive supranuclear palsy, behavior variant FTD (bvFTD) as a group with either tau or TDP-43 pathology, and healthy controls. EV tau ratios were low in progressive supranuclear palsy and high in bvFTD with tau pathology. EV TDP-43 levels were high in ALS and in bvFTD with TDP-43 pathology. Both markers discriminated between the diagnostic groups with area under the curve values >0.9, and between TDP-43 and tau pathology in bvFTD. Both markers strongly correlated with neurodegeneration, and clinical and neuropsychological markers of disease severity. Findings were replicated in an independent validation cohort of 292 patients including 34 genetically confirmed cases. Taken together, the combination of EV TDP-43 levels and EV 3R/4R tau ratios may aid the molecular diagnosis of FTD, FTD spectrum disorders and ALS, providing a potential biomarker to monitor disease progression and target engagement in clinical trials.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a minimally - invasive biomarker for detecting molecular pathologies in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Specifically, the study aims to distinguish different pathological types of FTD and ALS by detecting different subtypes (3R and 4R tau) of TDP - 43 protein and tau protein in plasma extracellular vesicles (EVs), thereby providing a potential diagnostic tool to assist in early diagnosis and monitoring of disease progression. ### Background and Problems 1. **Background**: - Currently, for neurodegenerative diseases such as FTD and ALS, there is a lack of effective disease - modifying therapies, partly due to the lack of biomarkers capable of detecting molecular pathologies. - Traditional molecular pathology diagnosis usually needs to be carried out after the patient's death, which limits the possibility of early diagnosis and treatment. - There is an urgent clinical need for a non - invasive method to detect the molecular pathology characteristics of these diseases. 2. **Specific Problems**: - How can different types of FTD and ALS be distinguished by the levels of TDP - 43 and tau proteins in plasma extracellular vesicles (EVs)? - Can these biomarkers be used as diagnostic tools to help in the early identification and monitoring of disease progression? ### Research Methods - **Sample Sources**: The study used plasma samples from 704 patients, including genetically and pathologically confirmed cases. - **Detection Methods**: The levels of TDP - 43 and tau proteins in plasma EVs were detected by immunoprecipitation and mass spectrometry analysis, and the ratio of 3R and 4R tau was calculated. - **Data Analysis**: The diagnostic accuracy of these biomarkers was evaluated using the receiver operating characteristic curve (ROC curve). ### Main Findings - **TDP - 43 Levels**: The level of TDP - 43 in plasma EVs was significantly increased in ALS patients, and also increased in FTD patients, but lower than that in ALS patients. - **3R/4R tau Ratio**: The 3R/4R tau ratio in plasma EVs was lower in patients with progressive supranuclear palsy (PSP) and higher in patients with behavioral variant frontotemporal dementia (bvFTD). - **Diagnostic Accuracy**: The combination of these two biomarkers showed high accuracy in distinguishing different types of FTD and ALS, with an AUC value greater than 0.9. ### Conclusions - By detecting the TDP - 43 and 3R/4R tau ratio in plasma EVs, different types of FTD and ALS can be effectively distinguished, providing a new tool for early diagnosis and monitoring of disease progression. - The combination of these biomarkers may be helpful for patient stratification in clinical trials and improve treatment effects.

Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS

Diagnostic Value of Isolated Plasma Biomarkers and Its Combination in Neurodegenerative Dementias: A Multicenter Cohort Study

Plasma Extracellular Vesicle: a Novel Biomarker for Neurodegenerative Disease Diagnosis

Molecular pathology markers of FTD and ALS in blood extracellular vesicles

A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD

Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics

In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use

Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia

Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD

EVolution in ALS diagnosis: molecular markers in extracellular vesicles

Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of Frontotemporal Dementia

Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia

Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative

Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis

Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration

Location and function of TDP-43 in platelets, alterations in neurodegenerative diseases and arising considerations for current plasma biobank protocols

Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

Blood-based CNS regionally and neuronally enriched extracellular vesicles carrying pTau217 for Alzheimer's disease diagnosis and differential diagnosis

Blood-based CNS Regionally and Neuronally Enriched Extracellular Vesicles Carrying Ptau217 for Alzheimer’s Disease Diagnosis and Differential Diagnosis